Multicenter, Prospective, Clinical Outcomes After Deployment of the Abluminal Sirolimus Coated Bio-Engineered Stent (Combo Bio- Engineered Sirolimus Eluting Stent) Post Market Registry

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 11 Jan 2022

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Anti-CD34 monoclonal antibody/sirolimus (Primary)
Indications Coronary artery disease; Coronary artery restenosis; Myocardial infarction
Focus Therapeutic Use
Acronyms REMEDEE-Registry

29 Aug 2018 Results presented at the ESC Congress 2018: Annual Congress of the European Society of Cardiology
02 Nov 2017 Results of pooled data from two trial (REMEDEE Registry and AIDA trial), were presented at the 29th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics.
02 Nov 2017 Final results of all-comers patients treated with COMBO stent with a follow-up of 3 years, were presented at the 29th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com